 |
|
Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Konstantinopoulos and colleagues raise the issue of the potential effect of concomitant aspirin use with TZDs on cardiac outcomes. We agree that aspirin use would have been an important variable to consider in our study. However, because aspirin is available without a prescription in Ontario, it is not covered by the provincial drug plan and is thus not captured by our databases.
Although the rate of cardiovascular events might be predicted to have been lower overall in patients taking aspirin,1 there is no reason to believe that aspirin treatment in our study was different between TZD and non-TZD users. First, history of cardiovascular disease (the primary indication for aspirin) was generally similar between oral hypoglycemic drug groups, and our analyses further matched and adjusted for cardiovascular variables. Second, we did consider other important medications in our study, and more than 64% of TZD-treated patients were taking at . . . [Full Text of this Article]
Lorraine L. Lipscombe, MD, MSc
lorraine.lipscombe@ices.on.ca
David A. Alter, MD, PhD
Institute for Clinical Evaluative Sciences
Toronto, Ontario, Canada
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lorraine L. Lipscombe, Tara Gomes, Linda E. Lévesque, Janet E. Hux, David N. Juurlink, and David A. Alter
JAMA. 2007;298(22):2634-2643.
ABSTRACT
| FULL TEXT
RELATED LETTER
Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events
Panagiotis A. Konstantinopoulos, Michalis V. Karamouzis, and Athanasios G. Papavassiliou
JAMA. 2008;299(13):1539.
EXTRACT
| FULL TEXT
|
